Calibration-Quality Cancer Nanotherapeutics

Perry, Jillian L.; Kai, Marc P.; Reuter, Kevin; Bowerman, Charles J.; Luft, J. Christopher; DeSimone, Joseph M.

doi:10.1007/978-3-319-16555-4_12

Cited by 9 publications

(8 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PEG molecular weight ranging from 2000 to 5000 g/mol was found to cause maximal reduction in protein adsorption when it was applied to relatively large polymeric particles with a size range of 160–270 nm 59 . The ideal density of PEG is highly dependent on the material the nanoparticle is made of 60,61 . Except for PEG, other hydrophilic and neutral polymers have been also used to prolong blood circulation times, including zwitterionic and carbohydrate coatings 62,63 .…”

Section: Design Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Design considerations for nanotherapeutics in oncology

Stylianopoulos

Jain

2015

Nanomedicine: Nanotechnology, Biology and Medicine

227

175

View full text Add to dashboard Cite

Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the fact that the Enhanced Permeability and Retention effect, which is the basis for the use of nanoparticles in cancer, can be also a barrier to the delivery of nanomedicines. A careful design of nanoparticle formulations can overcome barriers posed by the tumor microenvironment and result in better treatments. In this review, we first discuss strengths and limitations of clinically-approved nanoparticles. Then, we evaluate design parameters that can be modulated to optimize intratumoral delivery. The benefits of active tumor targeting and drug release rate on intratumoral delivery and treatment efficacy are also discussed. Finally, we suggest specific design strategies that should optimize delivery to most solid tumors and discuss under what conditions active targeting would be beneficial.

show abstract

Section: Design Considerationsmentioning

confidence: 99%

“…For stimuli-responsive nanoparticles release rates will also depend on the intensity and efficiency of the stimulus. In any case, the ideal condition is for the nanoparticle to allow release of the drug only when it enters into the tumor tissue 61 .…”

Section: Targeted Nanomedicines: the Interplay Among Interstitial Difmentioning

confidence: 99%

Design considerations for nanotherapeutics in oncology

Stylianopoulos

Jain

2015

Nanomedicine: Nanotechnology, Biology and Medicine

227

175

View full text Add to dashboard Cite

show abstract

“…In addition to a carrier's affinity, its geometry and flexibility regulate pharmacokinetics, circulation, tissue permeation, and interactions with cells [190][191][192][193][194]. Carrier size is a factor in route of administration, target access, and pharmacokinetics.…”

Section: Carrier Geometry and Flexibilitymentioning

confidence: 99%

Targeting drug delivery in the vascular system: Focus on endothelium

Glassman

Myerson

Ferguson

et al. 2020

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…Overall, spherical carriers smaller than tens of nanometers can be injected using diverse vascular, muscular and dermal routes, whereas carriers larger than few hundred nanometers can be administered via large vessels and airways [173–177]. The shape further modulates delivery: for example, non-spherical carriers circulate longer and avoid uptake by defense cells more effectively than spherical counterparts, whereas propeller-shape nanoparticles reach more deep deposition sites in the airways than spherical ones [81,178]…”

Section: Control Of Dds Targetingmentioning

confidence: 99%

Targeted endothelial nanomedicine for common acute pathological conditions

Shuvaev

Brenner

Muzykantov

2015

Journal of Controlled Release

View full text Add to dashboard Cite

Endothelium, a thin monolayer of specialized cells lining the lumen of blood vessels is the key regulatory interface between blood and tissues. Endothelial abnormalities are implicated in many diseases, including common acute conditions with high morbidity and mortality lacking therapy, in part because drugs and drug carriers have no natural endothelial affinity. Precise endothelial drug delivery may improve management of these conditions. Using ligands of molecules exposed to the bloodstream on the endothelial surface enables design of diverse targeted endothelial nanomedicine agents. Target molecules and binding epitopes must be accessible to drug carriers, carriers must be free of harmful effects, and targeting should provide desirable sub-cellular addressing of the drug cargo. The roster of current candidate target molecules for endothelial nanomedicine includes peptidases and other enzymes, cell adhesion molecules and integrins, localized in different domains of the endothelial plasmalemma and differentially distributed throughout the vasculature. Endowing carriers with an affinity to specific endothelial epitopes enables an unprecedented level of precision of control of drug delivery: binding to selected endothelial cell phenotypes, cellular addressing and duration of therapeutic effects. Features of nanocarrier design such as choice of epitope and ligand control delivery and effect of targeted endothelial nanomedicine agents. Pathological factors modulate endothelial targeting and uptake of nanocarriers. Selection of optimal binding sites and design features of nanocarriers are key controllable factors that can be iteratively engineered based on their performance from in vitro to pre-clinical in vivo experimental models. Targeted endothelial nanomedicine agents provide antioxidant, anti-inflammatory and other therapeutic effects unattainable by non-targeted counterparts in animal models of common acute severe human disease conditions. The results of animal studies provide the basis for the challenging translation endothelial nanomedicine into the clinical domain.

show abstract

Calibration-Quality Cancer Nanotherapeutics

Cited by 9 publications

References 69 publications

Design considerations for nanotherapeutics in oncology

Design considerations for nanotherapeutics in oncology

Targeting drug delivery in the vascular system: Focus on endothelium

Targeted endothelial nanomedicine for common acute pathological conditions

Contact Info

Product

Resources

About